Whatever

Cognizant may have good reasons for buying healthcare IT provider TriZetto for $2.7 bln. But promises of revenue synergies mixed with jargon should provoke investor skepticism, not an immediate 2 pct pop in the buyer’s shares. It’s a symptom of simmering M&A exuberance.